drugset / Trial / NCT01194427
A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer
Phase 2
Terminated
2 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelBasic science
Summary
This research study is designed to look at the effects of the combination of vorinostat (Suberoylanilide Hydroxamic Acid or Zolinza) and tamoxifen on breast cancer tissue. The investigators will do this by comparing tissues from the original breast biopsy to tissues obtained after taking vorinostat and tamoxifen for 2 weeks.
Timeline
- Start
- 2011-03
- Primary completion
- 2011-11
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tamoxifen | Small molecule | 20 mg | Oral |
| Subject | Vorinostat | Small molecule | 400 mg | Oral |